NCT05237726 - Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients | Biotech Hunter

Enrollment

20

Participants

Timeline

Start Date

April 5, 2020

Primary Completion Date

February 28, 2022

Study Completion Date

February 28, 2022

Conditions

Burns

Interventions

DRUG

Enoxaparin 40 mg q24 hours

Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

DRUG

Enoxaparin 30 mg q12 hours

Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

DRUG

Unfractionated heparin 5000 U q8 hours

Severely burn injuries (BSA≥20%) will be assigned to 3 modality regimens of pharmacological VTE prophylaxis: Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours.

Trial Locations (1)

11426

King Abdulaziz Medical City, Riyadh